Korro Bio Appoints New Director, Officer Compensation Details
Ticker: KRRO · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1703647
| Field | Detail |
|---|---|
| Company | Korro Bio, Inc. (KRRO) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, compensation
TL;DR
Korro Bio swapped a director and updated exec pay – board shakeup incoming?
AI Summary
Korro Bio, Inc. announced on February 11, 2025, the departure of Director Dr. Peter S. Kim and the election of Dr. David L. Donabedian as a new director. The company also reported on compensatory arrangements for its officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding strategic direction and operational stability.
Key Players & Entities
- Korro Bio, Inc. (company) — Registrant
- Dr. Peter S. Kim (person) — Departing Director
- Dr. David L. Donabedian (person) — Newly Elected Director
- February 11, 2025 (date) — Date of Report
FAQ
Who is Dr. David L. Donabedian and what is his background?
The filing does not provide specific details on Dr. David L. Donabedian's background or qualifications beyond his election as a director.
What were the reasons for Dr. Peter S. Kim's departure?
The filing states Dr. Peter S. Kim's departure but does not provide specific reasons for his departure.
What specific compensatory arrangements were discussed for the officers?
The filing indicates that compensatory arrangements of certain officers are being reported, but the specific details of these arrangements are not provided in this summary section.
Is this a routine board change or does it signal a strategic shift for Korro Bio?
The filing does not explicitly state whether this is a routine change or signals a strategic shift; it only reports the event.
When did Dr. Donabedian's directorship officially begin?
The filing indicates the election of Dr. David L. Donabedian as a director occurred on or before February 11, 2025, the date of the report.
Filing Stats: 737 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-02-11 16:05:17
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share KRRO The Nasdaq Capital M
Filing Documents
- d892089d8k.htm (8-K) — 24KB
- 0001193125-25-024305.txt ( ) — 147KB
- krro-20250211.xsd (EX-101.SCH) — 3KB
- krro-20250211_lab.xml (EX-101.LAB) — 18KB
- krro-20250211_pre.xml (EX-101.PRE) — 11KB
- d892089d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KORRO BIO, INC. Date: February 11, 2025 By: /s/ Ram Aiyar Name: Ram Aiyar Title: President and Chief Executive Officer